small intestinal bacterial overgrowth
Conditions
Interventions
Study Group:Yangwei granule, rifaximin
Control group:rifaximin
Sponsors
Foshan Fosun Chancheng Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients of both sexes aged 18-75 years at the baseline visit; 2. Clinical symptoms included abdominal distension, belching, abdominal pain, diarrhea, malnutrition, emaciation, etc. 3. patients with positive methane-hydrogen breath test; 4. Patients should be aware of the research content, have a basic understanding of the pharmacological effects and possible adverse reactions of the trial drugs, and sign an informed consent.
Exclusion criteria
Exclusion criteria: 1. patients who had used laxative, gastrointestinal motility, antipsychotic, or antibiotic drugs in the past 2 weeks; 2. those who received colonoscopic air barium radiography, colonoscopy or enema within the past 2 weeks; 3. patients allergic to Yangwei granule, rifaximin or rifamycin; 4. patients with intestinal obstruction; 5. poor compliance and inability to cooperate with the examination; 6. have participated in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SIBO negative conversion rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence rate of adverse events;Gastrointestinal Symptom Grading Score; | — |
Countries
China
Contacts
Public ContactTan Xiaojun
Foshan Fosun Chancheng Hospital
Outcome results
None listed